FCP
EGRX

Fidelis Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Fidelis Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,762
Closed -$54.2K – 430
2024
Q2 		$54.2K Buy
+12,762
New +$55.6K 0.01% 373

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fidelis Capital Partners's EGRX Position: Q3 2024 in Review

Fidelis Capital Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 12,762 shares — an estimated $54.2K sold.

Fidelis Capital Partners first reported a position in EGRX in Q2 2024 and held it in 1 quarter. The position peaked at $54.2K in Q2 2024. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Fidelis Capital Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Fidelis Capital Partners sold 12,762 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $54.2K.
  • Fidelis Capital Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2024 and held it in 1 quarter.
  • Fidelis Capital Partners's Eagle Pharmaceuticals, Inc. position peaked at $54.2K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Fidelis Capital Partners's 13F filing for Q3 2024, filed 25 Oct 2024.